SleepCare: obstructive sleep apnoea screening using mobile health technology

2014 ◽  
Author(s):  
J. Daly ◽  
A. Roebuck ◽  
P. Gilfriche ◽  
J. Behar ◽  
M. Morys ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Mobile Health ◽  
Health Technology ◽  
Sleep Apnoea ◽  
Mobile Health Technology ◽  
Obstructive Sleep

scholarly journals Mobile health application to support CPAP therapy in obstructive sleep apnoea: design, feasibility and perspectives

2020 ◽  
Vol 6 (1) ◽  
pp. 00220-2019 ◽  
Author(s):  
Monique Suarez-Giron ◽  
Onintza Garmendia ◽  
Vera Lugo ◽  
Concepción Ruiz ◽  
Neus Salord ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Mobile Health ◽  
External Validation ◽  
Sleep Apnoea ◽  
Mobile App ◽  
Cpap Therapy ◽  
Internal Validation ◽  
Clinical Control ◽  
Obstructive Sleep

BackgroundCurrent continuous positive airway pressure (CPAP) devices can be monitored remotely; however, in-person visits are kept for clinical follow-up in order to promote CPAP use and resolve potential side-effects. Mobile health is a promising way to provide remote and easy clinical control for CPAP follow-up and support. We aimed to evaluate the feasibility and acceptance by obstructive sleep apnoea (OSA) patients and healthcare professionals of a newly designed mobile app (Appnea-Q) to promote clinical control through a self-monitoring tool for patients with CPAP supervised by sleep professionals.MethodsAppnea-Q incorporates a simple follow-up questionnaire with automated responses, together with frequent problems and lifestyle recommendations sections. Feasibility, acceptance and usefulness were assessed. First, an internal validation was performed during outpatient CPAP follow-up visits with sleep professionals from various sleep units. Second, an external validation was performed in a subgroup of 15 patients at home.ResultsMost patients (n=75) considered the app useful and were willing to use it and recommend it (72–88%). Up to 64.87% agreed on its capacity to reduce hospital visits. Appnea-Q was rated as acceptable (79.37±19.29) by the system usability score. Sleep professionals (n=30) concurred on its usefulness for OSA patient follow-up, particularly during the first month of CPAP therapy. The external validation showed its feasibility among 11 out of 15 patients and their data were received accordingly on the professionals' web platform.ConclusionsAccording to our validation process, and the viewpoints of the patients and professionals, our new mobile app is a feasible and well-received tool for personal OSA management. Future clinical trials should substantiate its performance and cost-effectiveness in the clinical arena.

The severity of obstructive sleep apnoea does not influence ambient IGF-I levels

2017 ◽  
Author(s):  
Julie Lynch ◽  
Nikolaos Kyriakakis ◽  
Mark Elliott ◽  
Dipansu Ghosh ◽  
Mitchell Nix ◽  
...  
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Obstructive Sleep ◽  
Igf I

Requirement of staged interventions in a complex case of Acromegaly and Obstructive Sleep Apnoea

2020 ◽  
Author(s):  
Mili Dhar ◽  
Jennifer Elias ◽  
Benjamin Field ◽  
Sunil Zachariah ◽  
Julian Emmanuel
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Complex Case ◽  
Obstructive Sleep

Obstructive sleep apnoea is highly prevalent in a bariatric surgical population

2020 ◽  
Author(s):  
Rachel Agius ◽  
Claudia Coelho ◽  
James Crane ◽  
Piya Sen Gupta ◽  
Barbara McGowan
Keyword(s):  
Obstructive Sleep Apnoea ◽  
Sleep Apnoea ◽  
Obstructive Sleep

What Non-Alcoholic Fatty Liver Disease Has Got to Do with Obstructive Sleep Apnoea Syndrome and viceversa?

2014 ◽  
Vol 23 (3) ◽  
pp. 291-299 ◽  
Author(s):  
Giovanni Tarantino ◽  
Vincenzo Citro ◽  
Carmine Finelli
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Obstructive Sleep Apnoea ◽  
Fatty Liver Disease ◽  
Sleep Apnoea ◽  
Obstructive Sleep Apnoea Syndrome ◽  
Alcoholic Fatty Liver ◽  
Sleep Apnoea Syndrome ◽  
Obstructive Sleep ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnoea syndrome (OSAS) are common conditions, frequently encountered in patients with obesity and/or metabolic syndrome. NAFLD and OSAS are complex diseases that involve an interaction of several intertwined factors. Several lines of evidence lend credence to an immune system derangement in these patients, i.e. the low grade chronic inflammation status, reckoned to be the most important factor in causing and maintaining these two illnesses. Furthermore, it is emphasized the main role of spleen involvement, as a novel mechanism. In this review the contribution of the visceral adiposity in both NAFLD and OSAS is stressed as well as the role of intermittent hypoxia. Finally, a post on the prevention of systemic inflammation is made.Abbreviations: ALT: alanine aminotransferase; BMI: body mass index; CCR2: chemokine (C-C motif) receptor 2; CRP: C-reactive protein; CPAP: continuous positive airway pressure; FFA: free fatty acid; IGF-I: insulin-like growth factor; IR: insulin resistance; IL-6: interleukin-6; IH: intermittent hypoxia; IKK-β: IκB kinase β; LPS: lipopolysaccharide; MCP-1: monocyte chemoattractant protein-1; NAFLD: non-alcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis; NEFA: non-esterified fatty acid; NF-κB: nuclear factor-κB; OSAS: obstructive sleep apnoea syndrome; PAI-1: plasminogen activator inhibitor-1; ROS: reactive oxygen species; TNF-α: tumor necrosis factor-α; T2D: type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document